Inositol for Insulin Resistance

Verdict: Promising for insulin markers, but unproven

Inositol consistently improves short-term insulin-resistance markers such as HOMA-IR and fasting insulin across several trials, but the evidence rests entirely on surrogate measures of low certainty, so it is best viewed as a promising adjunct rather than a proven treatment for insulin resistance.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

Inositol earns a Preliminary (B) grade because the direction of effect is consistent across several meta-analyses. A 2025 GRADE-assessed review of 18 RCTs (PMID 41163174, n=898) found it lowered HOMA-IR (WMD -1.21) and fasting insulin (-4.74 microU/mL), and an earlier PCOS meta-analysis (PMID 29042448, n=496) reported similar reductions. A 2022 meta-analysis (PMID 35889788, n=1321) also found 4 g/day myo-inositol cut gestational-diabetes incidence by roughly 70% (RR 0.30).

The grade stays at B rather than higher for three reasons. Every measured benefit is a surrogate marker, not a hard clinical endpoint; the 2024 International PCOS Guideline meta-analysis (PMID 38163998, n=2230) rated certainty Very Low, called the evidence limited and inconclusive, and found no advantage over metformin; and the large NiPPeR RCT (PMID 33782086, n=1729) found no glycemic benefit when inositol was started preconception in a general population, suggesting the effect depends heavily on who takes it and when.

Regulators and clinics offer no endorsement that would lift the grade. The FDA treats inositol only as a GRAS food nutrient, the UK NHS notes the Inofolic combination helped PCOS metabolic markers in initial studies but does not recommend it as first-line, and WHO/Codex recognizes it solely as an infant-formula nutrient. Mayo Clinic and Harvard Health maintain no inositol fact sheet and professional societies are silent, hence published with warning.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.63
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
77%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.633
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (4 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Inositol supplementation efficacy in improving key cardiometabolic and anthropometric indices: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials
PMID: 41163174 2025 統合分析 n = 898
Finding: Inositol supplementation across 18 RCTs significantly reduced HOMA-IR (WMD -1.21, 95% CI -1.58 to -0.85, p<0.001) and fasting insulin (WMD -4.74 μU/mL, 95% CI -6.16 to -3.32, p<0.001); fasting glucose also fell (WMD -7.25 mg/dL, 95% CI -10.98 to -3.52, p<0.001).
Effect size: WMD HOMA-IR -1.21; fasting insulin -4.74 μU/mL; fasting glucose -7.25 mg/dL
View on PubMed
Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
PMID: 29042448 2017 統合分析 n = 496
Finding: Across 9 RCTs (247 cases, 249 controls) myo-inositol significantly decreased fasting insulin (SMD -1.021 μU/mL, 95% CI -1.791 to -0.251, p=0.009) and HOMA index (SMD -0.585, 95% CI -1.145 to -0.025, p=0.041).
Effect size: SMD fasting insulin -1.021 μU/mL; HOMA index -0.585
View on PubMed
Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines
PMID: 38163998 2024 統合分析 n = 2,230
Finding: Across 30 trials (2230 participants; 19 pooled) myo-inositol plus folic acid reduced HOMA-IR versus folic acid (MD -1.24, 95% CI -1.50 to -0.99) but GRADE certainty was Very Low; versus metformin no difference (MD -0.08, 95% CI -0.57 to 0.41, Low certainty). Authors concluded evidence is limited and inconclusive.
🟠 Limited quality Effect size: MD HOMA-IR -1.24 (vs folic acid, Very Low certainty); -0.08 (vs metformin)
View on PubMed
Inositol Nutritional Supplementation for the Prevention of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
PMID: 35889788 2022 統合分析 n = 1,321
Finding: Across 7 RCTs (1321 participants) 4 g/day myo-inositol lowered GDM incidence (RR 0.30, 95% CI 0.18-0.49, p<0.00001) and reduced fasting glucose (MD -4.20 mg/dL), 1-hour glucose (MD -8.75) and 2-hour glucose (MD -8.59 mg/dL, all p<0.00001).
Effect size: RR GDM 0.30; fasting glucose MD -4.20 mg/dL
View on PubMed
Myo-Inositol, Probiotics, and Micronutrient Supplementation From Preconception for Glycemia in Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial
PMID: 33782086 2021 隨機對照試驗 n = 1,729
Finding: In 1729 women planning conception, the myo-inositol-enriched formulation did NOT lower maternal glycemia at 28 weeks and did not reduce GDM incidence; it did reduce preterm birth. Contrasts with smaller at-risk-population trials.
⚠️ Industry-funded Effect size: No significant effect on 28-week glycemia or GDM incidence
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Neutral
Inositol is recognized as Generally Recognized As Safe (GRAS) for use as a nutrient supplement; affirmed under 21 CFR 184.1370. source↗
L4b EU EFSA
Neutral
L4c UK NHS
Neutral
A commercially available supplement called Inofolic, which is a combination of Myo Inositol and folic acid, has shown benefit in initial studies to improve the metabolic defect in PCOS and make menstrual cycles more regular. source↗
L4d TW TFDA / 衛福部
Neutral
嬰兒配方食品及較大嬰兒配方輔助食品之檢驗值應符合中華民國國家標準(CNS)所定之標準。 source↗
L4e WHO
Neutral
Minimum 4 mg/100 kcal of myo-inositol; Guidance Upper Level (GUL) 40 mg/100 kcal. [Codex Standard for Infant Formula and Formulas for Special Medical Purposes Intended for Infants, CODEX STAN 72-1981] source↗
L5a NIH Office of Dietary Supplements
Cautious
L5c Cleveland Clinic
Cautious
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-insulin-resistance-INT-inositol-001 繁體中文版 →